1 Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir, 2 Patients with server diseases of the blood system, 3 Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit, 4 Patients with alcoholism or are taking hepatotoxic drugs, 5 Patients with renal impairment (estimated glomerular filtration rate [eGFR]< 30 mL/min/1.73m2, using the MDRD method), 6 Patients with 6-phosphate dehydrogenase deficiency, 7 History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months, New York Heart Association (NYHA) level ?-?, 8 QTc=480ms 9 uncorrected patients with hypokalemia or hypokalemia 10Patients with retinopathy, fundus lesions, macular degeneration, 11 Patients with psychiatric disorders, 12? Patients with pancreatitis, 13? Patients with server auditory damage, 14? Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age, 15? Patients with medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation, or drugs that can increase adverse reactions, etc., 16? Patients were not eligible for this trial based on Investigator's considerationsPatients with a history of malignant tumor in the last 5 years.

1 Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir, 2 Patients with server diseases of the blood system, 3 Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit, 4 Patients with alcoholism or are taking hepatotoxic drugs, 5 Patients with renal impairment (estimated glomerular filtration rate [eGFR]< 30 mL/min/1.73m2, using the MDRD method), 6 Patients with 6-phosphate dehydrogenase deficiency, 7 History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months, New York Heart Association (NYHA) level ?-?, 8 QTc=480ms 9 uncorrected patients with hypokalemia or hypokalemia 10Patients with retinopathy, fundus lesions, macular degeneration, 11 Patients with psychiatric disorders, 12? Patients with pancreatitis, 13? Patients with server auditory damage, 14? Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age, 15? Patients with medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation, or drugs that can increase adverse reactions, etc., 16? Patients were not eligible for this trial based on Investigator's considerationsPatients with a history of malignant tumor in the last 5 years.